維康藥業(300878.SZ):收到參丹通腦滴丸I期臨牀試驗總結報吿
格隆匯1月17日丨維康藥業(300878.SZ)公佈,公司於近日收到參丹通腦滴丸在健康受試者中的安全性、耐受性及藥代動力學的隨機、雙盲、安慰劑對照、單次/連續給藥I期臨牀試驗的總結報吿。
研究結果表明,參丹通腦滴丸在健康受試者中的隨機、雙盲、安慰劑對照、單次/連續給藥I期臨牀試驗中具有良好的安全性和耐受性,同時在連續給藥健康受試者中檢測到代表性成分阿魏酸、丹酚酸B、人蔘皂苷Rb1血漿暴露情況。
截止公吿日,在CDE藥物臨牀試驗登記與信息公示平台上,已登記的用於中風治療的滴丸類藥物為4個:參丹通腦滴丸,銀杏內酯滴丸,清腦宣竅滴丸,舒腦欣滴丸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.